Abstract
Purpose. The purpose of this work was to replace Cremophor-EL in the commercial paclitaxel intravenous formulation, Taxol®, using a novel high-throughput combinatorial formulation approach.
Methods. Full factorial combinations of 12 generally regarded as safe excipients at three different concentrations were screened using an automated liquid dispenser. The hit formulations were further optimized to give the final optimized formulation TPI-1. TPI-1 was then tested in rats to compare its pharmacokinetic profile to Taxol®.
Results. Of the 9,880 combinations tested in the initial screen, 19 were identified as hit combinations. These were further optimized to give the final formulation TPI-1. When tested in rats, TPI-1 was well tolerated at both the low and high doses of 5 mg/kg and 10 mg/kg, whereas Taxol® killed all the rats at the high dose. TPI-1 experienced slower elimination compared to Taxol®. Similar to Taxol®, TPI-1 also exhibited nonlinear pharmacokinetics.
Conclusions. This study demonstrated the power of a high-throughput combinatorial approach for alternative paclitaxel formulations. We believe that this approach can be applied to drug formulation in general and it can improve the speed and efficiency of drug formulation design.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. C. Wani, H. L. Taylor, and M. E. Wall. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent form Taxus brevifolia. J. Am. Chem. Soc. 93:2325-2327 (1971).
A. K. Singla, A. Garg, and D. Aggarwal. Paclitaxel and its formulations. Int. J. Pharm. 235:179-192 (2002).
J. D. Adams, K. P. Flora, B. R. Goldspiel, J. W. Wilson, S. G. Arbuck, and R. Finley. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr. 15:141-147 (1993).
P. P. Constantinides, K. J. Lambert, A. K. Tustian, B. Schneider, S. Lalji, W. Ma, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Formulation development and antitumor activity of a filter sterilizable emulsion of paclitaxel. Pharm. Res. 17:175-182 (2000).
R. M. Straubinger, A. S. Sharma, M. Murray, and E. Mayhew. Novel Taxol formulations: Taxol-containing liposomes. J. Natl. Cancer Inst. Monogr. 15:69-78 (1993).
P. Simamora, R. Dannenfelser, S. E. Tabibi, and S. H. Yalkowsky. Emulsion formulations for intravenous administration of paclitaxel. PDA J. Pharm. Sci. Tech. 52:170-172 (1998).
U. S. Sharma, S. V. Balasubramanian, and R. M. Straubinger. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci. 84:1223-1230 (1995).
A. J. Bailer. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 16:303-309 (1988).
L. van Zuylen, J. Verweij, and A. Sparreboom. Role of formulation vehicles in Taxane pharmacology. Invest. New Drugs 19:125-141 (2001).
H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37:1590-1598 (2001).
A. Sparreboom, O. van Tellingen, W. J. Nooijen, and J. H. Beijnen. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1-17 (1998).
A. Sparreboom, O. van Tellingen, W. J. Nooijen, and J. H. Beijnen. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 56:2112-2115 (1996).
O. van Tellingen, M. T. Huizing, V. R. Nannan Panday, J. H. M. Schellens, W. J. Nooijen, and J. H. Beijnen. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer 81:330-335 (1999).
A. Sparreboom, L. van Zuylen, E. Brouwer, W. J. Loos, P. de Bruijin, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59:1454-1457 (1999).
L. van Zuylen, M. O. Karlsson, J. Verweij, E. Brouwer, P. de Bruijin, K. Nooter, G. Stoter, and A. Sparreboom. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47:309-318 (2001).
D. S. Sonnichsen and M. V. Relling. Clinical Pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27:256-269 (1994).
J. H. Beijnen, M. T. Huizing, W. W. ten Bokkel Huinink, C. H. N, Veenhof, J. B. Vermorken, G. Giaccone, and H. M. Pinedo. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Semin Oncol. 21:53-62 (1994).
U. Vaishampayan, M. D. Ralph, E. Parchment, B. R. Jasti, and M. Hussain. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54:22-29 (1999).
S. Nema, R. J. Washkuhn, and R. J. Brendel. Excipients and their use in injectable products. PDA J. Pharm. Sci. Tech 51:166-171 (1997).
O. van Tellingen, J. H. Beijnen, J. Verweij, E. J. Scherrenburg, W. J. Nooijen, and A. Sparreboom. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res. 5:2918-2924 (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, H., Zhang, Z., McNulty, C. et al. A High-Throughput Combinatorial Approach for the Discovery of a Cremophor EL-Free Paclitaxel Formulation. Pharm Res 20, 1302–1308 (2003). https://doi.org/10.1023/A:1025021603288
Issue Date:
DOI: https://doi.org/10.1023/A:1025021603288